Tcr2 Therapeutics Inc (TCRR)

NASDAQ
1.77
-0.04(-2.21%)
After Hours
1.77
0.00(0.00%)
- Real-time Data
  • Volume:
    101,536
  • Day's Range:
    1.77 - 1.88
  • 52 wk Range:
    1.60 - 8.82

TCRR Overview

Prev. Close
1.81
Day's Range
1.77-1.88
Revenue
-
Open
1.8
52 wk Range
1.6-8.82
EPS
-2.99
Volume
101,536
Market Cap
68.33M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
257,192
P/E Ratio
-1.21
Beta
1.77
1-Year Change
-77.76%
Shares Outstanding
38,606,424
Next Earnings Date
Nov 16, 2022
What is your sentiment on Tcr2 Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Tcr2 Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Tcr2 Therapeutics Inc Analysis

Tcr2 Therapeutics Inc Company Profile

Tcr2 Therapeutics Inc Company Profile

Employees
164

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company’s lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Read More

Analyst Price Target

Average12.78 (+622.03% Upside)
High20
Low2
Price1.77
No. of Analysts9
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • what happens here is it worths to entry in TCRR ?
    0
    • Seems quite silent here...
      0
      • 27 - is this a good price?
        1
        • any opinion Alexandr ?
          0
      • price target raised to $58 from $33 at Mizuho price target raised to $45 from $35 at Piper Sandler price target raised to $65 from $46 at BMO Capital price target raised to $37 from $32 at H.C. Wainwright
        0
        • the best paper ever)
          0